Full Breakdown
Australian Tech Entrepreneur Develops Custom mRNA Vaccine for Dying Dog
3/17/2026, 7:27:29 AM
Innovative Approach to Canine Cancer Treatment
When Paul Conyngham, an Australian tech entrepreneur, faced the heartbreaking diagnosis of his 8-year-old dog Rosie, who had advanced mast cell cancer, he turned to an unconventional partner for help: ChatGPT. After spending significant funds on chemotherapy and surgery with minimal results, Conyngham sought to leverage artificial intelligence to find a potential cure for his pet. He initiated the process by asking ChatGPT for possible treatments, which led him to explore immunotherapy.
Conyngham collaborated with the UNSW Ramaciotti Centre for Genomics to sequence Rosie’s DNA, a process that cost approximately $3,000. According to UNSW associate professor Martin Smith, sequencing allows for the profiling of tumors to identify mutations responsible for the disease. Utilizing his 17 years of experience in machine learning and data analysis, Conyngham processed the genetic data to identify mutated proteins and matched them with potential drugs, ultimately creating a blueprint for a personalized mRNA vaccine.
Overcoming Challenges in Vaccine Development
Despite the innovative approach, Conyngham encountered significant hurdles, particularly in obtaining ethics approval for a drug trial on Rosie. He described the bureaucratic process as more challenging than the actual vaccine development, dedicating substantial time to prepare a comprehensive 100-page document for approval.
Fortunately, Rachel Allavena, a canine immunotherapy professor at the University of Queensland, joined the effort, leveraging her expertise in experimental immunotherapies to facilitate the process. The bespoke vaccine was eventually delivered to Allavena’s laboratory in Gatton, requiring a 10-hour journey for Conyngham and Rosie.
Positive Outcomes and Future Implications
Rosie received her first vaccine shot in December, followed by a booster shot last month. The results have been promising; the once tennis-ball-sized tumor on her leg has shrunk to half its size, and her overall health has improved significantly. Conyngham noted, “I’m under no illusion that this is a cure, but I do believe this treatment has bought Rosie significantly more time and quality of life.”
As Conyngham works on a second vaccine for another tumor, Smith expressed hope that this case could inspire advancements in cancer treatments for humans, questioning, “If we can do this for a dog, why aren’t we rolling this out to all humans with cancer?”
Verbatim Quotes
- “The red tape was actually harder than the vaccine creation, and I was trying to get an Australian ethics approval to run a drug trial on Rosie,” — Paul Conyngham, Tech Entrepreneur
- “It raises the question, if we can do this for a dog, why aren’t we rolling this out to all humans with cancer?” — Martin Smith, UNSW Associate Professor
Criticism & Opposition
While the case has garnered attention for its innovative approach, some experts may raise concerns regarding the ethical implications of using personalized mRNA vaccines in veterinary medicine and the potential for broader applications in human medicine.
What's Next
Conyngham continues to develop additional vaccines for Rosie and aims to contribute to the ongoing research in canine and human cancer treatments, potentially paving the way for new therapeutic strategies.
